Abstract. Parkinson's disease (PD) is a widespread ageassociated neurodegenerative disorder. Current treatment is symptomatic rather than curative. However, stem cell replacement therapies may have the potential to offer curative treatment. In this study, we demonstrate that rat CD49f + spermatogonial stem cells (rSSCs) can be induced to become functional dopaminergic neuron-like cells in vitro. Furthermore, when rSSCs were transplanted into 6-hydroxydopamine (6-OHDA)-treated PD rats, the results indicated that rSSCs expressed multiple neuron cell markers and were ameliorative to behavioral recovery in PD rats after induction both in vitro and in vivo. In addition, rSSCs demonstrated increased activity in the regeneration of dopaminergic neuron-like cells, increased migration distances and were associated with improvement in animal behavior in the PD rat model. Therefore, rSSCs could be a source of dopaminergic neuron-like cells with potential benefit in cell replacement therapy for PD.
IntroductionParkinson's disease (PD) is characterized by a progressive loss of midbrain substantia nigra dopaminergic (DA) neurons that project to the striatum, and these neurons are responsible for the main motor symptoms that characterize the disease (1,2). PD is a major neurodegenerative disease that affects almost 2% of the population over the age of 65 years. At present, cell replacement therapies may provide the most promising prospect for curative treatment (3-7). If cells can be placed in the brain to produce suitable, controlled levels of dopamine release in the striatum, this raises the possibility that the disease process could be attenuated and motor function restored in affected patients.However, regenerative and cell replacement therapies face several important challenges. Firstly, the main symptoms of PD result from a loss of midbrain DA neurons, but other cell types are also affected. Secondly, a further challenge for fetal tissue grafting is the poor survival of DA neurons following transplantation (1). Previous studies have indicated that not only neural stem cells, but also embryonic stem cells (ESCs) and induced pluripotent stem (iPS) cells can be induced to differentiate into dopaminergic neurons and to provide behavioral improvement in 6-hydroxydopamine (6-OHDA)-lesioned rat models (3-10). This suggests that these stem cells have potential for the use of cell therapy in the management of neurodegenerative diseases.For many years, scientists have been looking for mechanisms that regulate the differentiation of stem cells. The answer is likely to be complex and to involve a variety of contributing factors (9). Despite intensive research over the past decades, little is known about how the self-renewal properties of these stem cells are maintained and how their cell fate is determined (3,11). In addition, some stem cells, such as ESCs, have not been used clinically due to ethical limitations. Indeed, studies have reported that iPS cells, if seeded into the mouse brain, can result in highly malignant teratocarci...